Characterisation of the anti-lymphoma activity of pracinostat reveals differential sensitivities of DLBCL cells to HDAC inhibitors
6 lymphoma cell lines (OCILY1, SUDHL4, TOLEDO, WSUDLCL2, PFEIFFER, SUDHL6) have been treated with DMSO, Vorinostat and Pracinostat. The transcriptome has been sequenced after 6hrs and 14 days from the treatment. The gene expression levels have been compared in order to elucidate the differencies and similarities for Vorinostat and Pracinostat compare to DMSO (control group). Overall design: Transcriptome profiles of 6hrs and 14days for 6 lymphoma cell lines treated with DMSO, Vorinostat and Pracinostat.